202 related articles for article (PubMed ID: 28676406)
1. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies.
Antonioli L; Novitskiy SV; Sachsenmeier KF; Fornai M; Blandizzi C; Haskó G
Drug Discov Today; 2017 Nov; 22(11):1686-1696. PubMed ID: 28676406
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
3. CD73-adenosine: a next-generation target in immuno-oncology.
Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
[TBL] [Abstract][Full Text] [Related]
4. CD73: an emerging checkpoint for cancer immunotherapy.
Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B
Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045
[TBL] [Abstract][Full Text] [Related]
5. Potential of CD73 as a target for cancer immunotherapy.
Jadidi-Niaragh F
Immunotherapy; 2019 Nov; 11(16):1353-1355. PubMed ID: 31578906
[No Abstract] [Full Text] [Related]
6. Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017-present).
Nocentini A; Capasso C; Supuran CT
Expert Opin Ther Pat; 2021 Oct; 31(10):867-876. PubMed ID: 33909515
[TBL] [Abstract][Full Text] [Related]
7. Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target.
Yang J; Liao X; Yu J; Zhou P
Curr Med Chem; 2018; 25(19):2260-2271. PubMed ID: 29345574
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
9. Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A
Varano F; Catarzi D; Vincenzi F; Pasquini S; Pelletier J; Lopes Rangel Fietto J; Espindola Gelsleichter N; Sarlandie M; Guilbaud A; Sévigny J; Varani K; Colotta V
Bioorg Med Chem Lett; 2020 May; 30(9):127067. PubMed ID: 32165041
[TBL] [Abstract][Full Text] [Related]
10. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.
Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K
Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546
[TBL] [Abstract][Full Text] [Related]
11. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.
Geoghegan JC; Diedrich G; Lu X; Rosenthal K; Sachsenmeier KF; Wu H; Dall'Acqua WF; Damschroder MM
MAbs; 2016; 8(3):454-67. PubMed ID: 26854859
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD73 therapy impairs tumor angiogenesis.
Allard B; Turcotte M; Spring K; Pommey S; Royal I; Stagg J
Int J Cancer; 2014 Mar; 134(6):1466-73. PubMed ID: 23982901
[TBL] [Abstract][Full Text] [Related]
14. Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface.
Rahimova R; Fontanel S; Lionne C; Jordheim LP; Peyrottes S; Chaloin L
PLoS Comput Biol; 2018 Jan; 14(1):e1005943. PubMed ID: 29377887
[TBL] [Abstract][Full Text] [Related]
15. Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays.
Allard B; Cousineau I; Spring K; Stagg J
Methods Enzymol; 2019; 629():269-289. PubMed ID: 31727245
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib.
Hallaj S; Heydarzadeh Asl S; Alian F; Farshid S; Eshaghi FS; Namdar A; Atyabi F; Masjedi A; Hallaj T; Ghorbani A; Ghalamfarsa G; Sojoodi M; Jadidi-Niaragh F
Life Sci; 2020 Oct; 259():118150. PubMed ID: 32726663
[TBL] [Abstract][Full Text] [Related]
17. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.
Loi S; Pommey S; Haibe-Kains B; Beavis PA; Darcy PK; Smyth MJ; Stagg J
Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11091-6. PubMed ID: 23776241
[TBL] [Abstract][Full Text] [Related]
18. Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production.
Du X; Moore J; Blank BR; Eksterowicz J; Sutimantanapi D; Yuen N; Metzger T; Chan B; Huang T; Chen X; Chen Y; Duong F; Kong W; Chang JH; Sun J; Zavorotinskaya T; Ye Q; Junttila MR; Ndubaku C; Friedman LS; Fantin VR; Sun D
J Med Chem; 2020 Sep; 63(18):10433-10459. PubMed ID: 32865411
[TBL] [Abstract][Full Text] [Related]
19. Targeting cancer-derived adenosine: new therapeutic approaches.
Young A; Mittal D; Stagg J; Smyth MJ
Cancer Discov; 2014 Aug; 4(8):879-88. PubMed ID: 25035124
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of Substituted 5'-Aminoadenosine Derivatives and Evaluation of Their Inhibitory Potential toward CD73.
Ghoteimi R; Nguyen VT; Rahimova R; Grosjean F; Cros-Perrial E; Uttaro JP; Mathé C; Chaloin L; Jordheim LP; Peyrottes S
ChemMedChem; 2019 Aug; 14(15):1431-1443. PubMed ID: 31264794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
